Qiansen Zhang

Qiansen Zhang

Auto-generated profile, based on publicly available information

Qiansen Zhang


Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 September 2020 in Cell Research
Verified
Journal Article
Closed access
PDF file
XLXiaoxiao Li
Xiaoxiao Li
QZQiansen Zhang
Qiansen Zhang
PGPeipei Guo
Peipei Guo
JFJie Fu
Jie Fu
LMLianghe Mei
Lianghe Mei
JGJiangtao Guo
Jiangtao Guo

4 February 2025 in Nature Immunology
Verified
Journal Article
Closed access
PDF file
JHJiacheng He
Jiacheng He
XCXiaolei Chai
Xiaolei Chai
QZQiansen Zhang
Qiansen Zhang
YWYang Wang
Yang Wang
YWYijie Wang
Yijie Wang
WLweiqiang lu
weiqiang lu

20 November 2019 in Science Translational Medicine
Verified
Journal Article
Closed access
PDF file
PLPing Liao
Ping Liao
YQYunguang Qiu
Yunguang Qiu
YMYiqing Mo
Yiqing Mo
JFJie Fu
Jie Fu
ZSZhenpeng Song
Zhenpeng Song
HYHuaiyu Yang
Huaiyu Yang
Agonists selectively targeting peripheral TWIK-related acid-sensitive K + 3 subunit–containing channels show potential as non-opioid analgesics.

3 February 2022 in Cell Research
Verified
Journal Article
Closed access
PDF file
QZQiansen Zhang
Qiansen Zhang
YRYimin Ren
Yimin Ren
YMYiqing Mo
Yiqing Mo
PGPeipei Guo
Peipei Guo
PLPing Liao
Ping Liao
RJRuotian Jiang
Ruotian Jiang

14 November 2022 in Clinical Cancer Research
Verified
Journal Article
Closed access
PDF file
HCHuang Chen
Huang Chen
WZWenbo Zhou
Wenbo Zhou
ABAiwu Bian
Aiwu Bian
QZQiansen Zhang
Qiansen Zhang
YMYing Miao
Ying Miao
ZYZhengfang Yi
Zhengfang Yi
Purpose: Pancreatic cancer is the worst prognosis among all human cancers, and novel effective treatments are urgently needed. Signal transducer and activator of transcription 3 (STAT3) has been demonstrated as a promising target for pancreatic cancer. Meanwhile, selectively targeted STAT3 with small molecule remains been challenging. Experimental Design: To specifically identify STAT3 inhibitors, more than 1.3 million compounds were screened by structure-based virtual screening and confirmed with the direct binding assay. The amino acid residues that WB436B bound to were verified by induced-fit molecular docking simulation, RosettaLigand computations, and site-directed mutagenesis. On-target effects of WB436B were examined by microscale thermophoresis, surface plasmon resonance, in vitro kinase assay, RNA sequencing, and selective cell growth inhibition assessment. In vivo studies were performed in four animal models to evaluate effects of WB436B on tumor growth and metastasis. Kaplan–Meier analyses were used to assess survival. Results: WB436B selectively bound to STAT3 over other STAT families protein, and in vitro antitumor activities were improved by 10 to 1,000 fold than the representative STAT3 inhibitors. WB436B selectively inhibits STAT3-Tyr705 phosphorylation, STAT3 target gene expression, and the viability of STAT3-dependent pancreatic cancer cells. WB436B significantly suppresses tumor growth and metastasis in vivo and prolongs survival of tumor-bearing mice. Mechanistic studies showed that WB436B have unique binding sites located in STAT3 Src homology 2 domain. Conclusions: Our work presents the first-in-class selective STAT3 inhibitor WB436B as a potential therapeutic candidate for the treatment of pancreatic cancer.

10 February 2024 in ACS Central Science
Verified
Journal Article
Open access
HCHuang Chen
Huang Chen
ABAiwu Bian
Aiwu Bian
WZWenbo Zhou
Wenbo Zhou
YMYing Miao
Ying Miao
JYJiangnan Ye
Jiangnan Ye
MLMingyao Liu
Mingyao Liu
Signal transducer and activator of transcription 3 (STAT3) is an attractive cancer therapeutic target. Unfortunately, targeting STAT3 with small molecules has proven to be very challenging, and for full activation of STAT3, the cooperative phosphorylation of both tyrosine 705 (Tyr705) and serine 727 (Ser727) is needed. Further, a selective inhibitor of STAT3 dual phosphorylation has not been developed. Here, we identified a low nanomolar potency and highly selective small-molecule STAT3 inhibitor that simultaneously inhibits both STAT3 Tyr705 and Ser727 phosphorylation. YY002 potently inhibited STAT3-dependent tumor cell growth in vitro and achieved potent suppression of tumor growth and metastasis in vivo. More importantly, YY002 exhibited favorable pharmacokinetics, an acceptable safety profile, and superior antitumor efficacy compared to BBI608 (STAT3 inhibitor that has advanced into phase III trials). For the mechanism, YY002 is selectively bound to the STAT3 Src Homology 2 (SH2) domain over other STAT members, which strongly suppressed STAT3 nuclear and mitochondrial functions in STAT3-dependent cells. Collectively, this study suggests the potential of small-molecule STAT3 inhibitors as possible anticancer therapeutic agents.